Michael S. Weiss
Executive ChairmanMr. Michael S. Weiss, also known as Mike, Esq., J.D., serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim President and Chief Executive Officer since March 2015 until April 24, 2017 and also served as its President until April 24, 2017. He serves as the Director at Cyprium Therapeutics, Inc. and Founded it in 2017. Mr. Weiss serves as Chairman of the Board at TG Therapeutics, Inc. since December 29, 2011. Mr. Weiss serves as the Chief Executive Officer and President of TG Therapeutics, Inc. (formerly, Manhattan Pharmaceuticals, Inc.) since December 29, 2011 and served as its Executive Chairman since December 29, 2011 until June 16, 2021. He co-founded Opus Point Partners, LLC in 2009 and serves as a Co-Portfolio Manager and has been its managing Partner and Principal since 2009. He is a Partner of Opus Point Partners. Mr. Weiss had been the Chairman of Checkpoint Therapeutics, Inc. since March 2015 until May 30, 2025 and also served as its Director since 2015 until May 30, 2025. He co-founded TG Therapeutics, Inc. in 2011. He has been Executive Vice Chairman of Strategic Development at Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) since February 20, 2014 and also serves as its Director. Mr. Weiss served in several capacities at Fortress Biotech. Mr. Weiss served as Interim Chief Executive Officer and President at Checkpoint Therapeutics, Inc. from March 2015 to December 2016 and Executive Chairman from March 2015 to December 2016. He served as Chief Executive Officer and Chairman of Keryx Biopharmaceuticals Inc. from December 2002 to April 23, 2009, where he helped it acquire and develop its lead drug Zerenex as well as executed a strategic alliance for Zerenex with Japan Tobacco, Inc. and Torii Pharmaceutical Co. Ltd. Since joined Keryx in December 2002, Mr. Weiss successfully completed the restructuring, an acquisition of a private cancer company, the initiation of a phase II/III clinical program for a lead drug candidate and two equity capital raising transactions from leading US-based biotechnology funds. He founded Access Oncology Inc. in 1999 and served as its Chief Executive Officer from 1999 to 2002. Mr. Weiss served as the Chief Executive Officer and Chairman of Cancer Education.com Inc. since April 1999. He served as the Secretary of Atlantic Pharmaceuticals Inc. He served as the Secretary of Binary Therapeutics Inc. and BG Development Corp. Mr. Weiss also served at Paligent Inc. He served as Senior Managing Director of Paramount Capital Investments, L.L.C. from November 1993 to March 1999. From 1993 to 1999, he was responsible for negotiating and executing private and public investments in biotechnology companies. He serves as the Chairman of Heavenlydoor.com Inc. (now Paligent Inc.). He had been the Chairman of National Holdings Corporation since September 21, 2016 until June 2018. He served as the Non-Executive Chairman of National Holdings Corporation from January 19, 2011 to April 14, 2012. From March 1999 to December 2002, he served as the Chairman of Access Oncology Inc. He served as Non-Executive Chairman of XTL Biopharmaceuticals Ltd. since August 2005 and also served as its Interim Non-Executive Chairman since March 15, 2005. He served as a Co-Chairman of CB Pharma Acquisition Corp. (now Origo Acquisition Corporation) from August 26, 2014 to June 10, 2016. He served as a Vice Chairman of Genta Incorporated from May 1997 to September 2005. He had been a Director at National Holdings Corporation since September 9, 2016 until June 11, 2018. He serves as a Member of the Board of Directors of several of the Fortress Biotech’s subsidiaries, including: Aevitas Therapeutics, Inc. Caelum Biosciences, Inc. Cellvation, Inc. Cyprium Therapeutics, Inc. and Tamid Bio, Inc. He has been a Director at Mustang Bio, Inc. since May 2015. He had been a Non-Executive Director of Avenue Therapeutics, Inc. since March 2015 to February 2018. He serves as a Director of Palatin Technologies Inc. and Helocyte Inc. He has been a Director of Fortress Biotech, Inc. since December 19, 2013. He has been a Director of TG Therapeutics, Inc. since December 29, 2011. Mr. Weiss serves as a Member of the Board of Directors of AVAX Technologies Inc. He served as a Director at TG Therapeutics, Inc. since 2011. He served as a Director of Pacific Pharmaceuticals since 1995. He served as Lead Director at Genta Incorporated since November 2002 and Director since 1997. He served as a Non-Executive Director of XTL Biopharmaceuticals Ltd. since December 1, 2004. He served as a Director of National Holdings Corporation from January 2011 to April 14, 2012. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. He served as a Director of Keryx Biopharmaceuticals Inc. since 2002. He served as a Director of Healthcare Integrated Services, Inc. since July 1998. He served as a Director of Binary Therapeutics Inc. and BG Development Corp. He is also Executive Vice Chairman of FBIO. He is a Member of Dean’s Advisory Board at School of Business at the University at Albany. He was an Investment Banker and Fund Manager in New York City, focused on biotech and life sciences. Mr. Weiss received a J.D. from Columbia Law School in 1991 and a B.S. in Finance from The University at Albany in 1984.
Positions
- Company NameMustang Bio, Inc.Stock CodeMBIOPositionExecutive ChairmanColleagues
- MSMichael S. WeissExecutive Chairman
- MLManuel LitchmanPresident, CEO, Interim CFO & Director
- PCPeter CarneyController & Interim Chief Accounting Officer
- GFGreg FurrowChief Quality Officer
- RMRobyn M. HunterCorporate Secretary
- NHNeil HerskowitzIndependent & Non-Executive Director
- AJAdam J. ChillIndependent Director
- LALindsay Allan RosenwaldNon-Executive Director
- Company NameTG Therapeutics, Inc.Stock CodeTGTXPositionChairman, CEO & PresidentColleagues
- SASean A. PowerCFO, Corporate Secretary & Treasurer
- JBJenna BoscoSenior Vice President of Corporate Communications
- AWAdam WaldmanChief Commercialization Officer
- LNLaurence N. CharneyLead Independent Director
- KHKenneth HobermanIndependent Director
- SLSagar LonialIndependent Director
- YEYann EchelardIndependent Director
- Company NameFortress Biotech, Inc.Stock CodeFBIOPositionExecutive Vice Chairman of Strategic Development & DirectorRelated SecuritiesColleagues
- LALindsay Allan RosenwaldExecutive Chairman, President & CEO
- DJDavid JinCFO & Head of Corporate Development
- XLXiaoqin LuChief Strategy Officer
- MSMichael S. WeissExecutive Vice Chairman of Strategic Development & Director
- JJJ. Jay LobellIndependent Director
- DKDov KleinIndependent Director
- JHJimmie Huling HarveyIndependent Director
